Clinical Trials Browser

Estrogen Receptor-positive Breast Cancer × palbociclib × 90 days × Clear all

NCT03633331 2026-04-29

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Phase 2 Completed

93 enrolled 16 charts

Estrogen Receptor-positive Breast Cancer